The Neuromuscular Junction in Crisis: Botulism and its Mimics

Dr Neeraj Manikath , claude.ai

Abstract

Botulism represents a rare but life-threatening disorder of neuromuscular transmission caused by botulinum neurotoxin. Despite advances in critical care, botulism continues to challenge clinicians with its protean manifestations, diagnostic complexity, and potential for respiratory failure. This review addresses the clinical recognition of botulism through its distinctive "descending" pattern of paralysis, differentiates it from common mimics, explores the four major toxinotypes, and discusses practical aspects of diagnosis including the role of edrophonium testing. We examine the logistics of securing antitoxin therapy and emphasize the prolonged recovery period requiring comprehensive neurorehabilitation. Understanding these facets is essential for intensivists managing patients with acute flaccid paralysis syndromes.

Keywords: Botulism, neuromuscular junction, flaccid paralysis, botulinum antitoxin, critical care

Introduction

Botulism, derived from the Latin botulus (sausage), was first described in the 18th century following outbreaks linked to contaminated meat products. The causative organism, Clostridium botulinum, produces one of the most potent biological toxins known to medicine, with an estimated human lethal dose of 1-3 ng/kg for botulinum neurotoxin type A.1 Despite its rarity—approximately 200 cases reported annually in the United States—botulism demands immediate recognition and intervention, as mortality can approach 5-10% even with optimal care, primarily from respiratory failure.2

The toxin's mechanism involves irreversible inhibition of acetylcholine release at the presynaptic neuromuscular junction, resulting in the characteristic flaccid paralysis. For the critical care physician, distinguishing botulism from its numerous mimics, particularly Guillain-Barré syndrome (GBS), myasthenia gravis, and other acute neuromuscular disorders, can mean the difference between timely antitoxin administration and prolonged, potentially fatal, paralysis.

The "Descending" Flaccid Paralysis: A Key Differentiator from Guillain-Barré

Pearl #1: Think "top-down" for botulism, "bottom-up" for GBS.

The hallmark clinical feature distinguishing botulism from its primary mimic, GBS, lies in the pattern of paralysis progression. Botulism classically presents with descending paralysis, beginning with bulbar symptoms and progressing caudally, whereas GBS characteristically demonstrates ascending paralysis starting in the lower extremities.3

The Classic Botulism Triad

The initial presentation of botulism follows a stereotypical pattern:

Bulbar dysfunction (12-36 hours post-exposure): Diplopia, dysarthria, dysphagia, and dysphonia—the "4 Ds"
Descending symmetric paralysis: Progressive weakness moving from cranial nerves to truncal and limb muscles
Autonomic dysfunction: Dilated unreactive pupils, dry mouth, constipation, urinary retention, orthostatic hypotension

Clinical Hack: The presence of dilated, poorly reactive pupils with preserved consciousness is virtually pathognomonic for botulism and rarely seen in GBS.4 However, pupillary abnormalities occur in only 50% of cases, so their absence does not exclude botulism.

Contrasting with Guillain-Barré Syndrome

Feature	Botulism	Guillain-Barré Syndrome
Progression	Descending	Ascending
Initial symptoms	Diplopia, dysphagia	Lower extremity weakness, paresthesias
Sensory involvement	Absent	Present (paresthesias, pain)
Pupils	Often dilated, sluggish	Normal
Autonomic features	Prominent (dry mouth, constipation, urinary retention)	Variable (cardiac arrhythmias, blood pressure lability)
CSF protein	Normal	Elevated (albuminocytologic dissociation)
Tendon reflexes	Decreased/absent	Decreased/absent
Fever	Absent	May be present

Oyster: Deep tendon reflexes in botulism can be preserved early in the disease course or may be depressed but rarely absent, creating diagnostic confusion. In contrast, areflexia is the rule in GBS.5

Other Important Mimics

Myasthenia Gravis (MG): Like botulism, MG presents with ocular and bulbar symptoms, but weakness in MG characteristically demonstrates fatigability (worsens with repetitive activity) and diurnal variation (worse at day's end). Ptosis with preserved pupillary reflexes favors MG. The edrophonium test (discussed below) can help differentiate these conditions.

Miller Fisher Syndrome: This GBS variant presents with the classic triad of ataxia, areflexia, and ophthalmoplegia. Unlike botulism, Miller Fisher syndrome typically includes prominent ataxia and does not progress to severe generalized paralysis.6

Stroke (particularly brainstem): Acute brainstem infarction can mimic botulism's bulbar symptoms. Key differentiators include the hyperacute onset in stroke (minutes to hours vs. 12-36 hours in botulism), altered consciousness in basilar thrombosis, and characteristic MRI findings. The presence of symmetric bilateral cranial neuropathies without encephalopathy should prompt consideration of botulism over stroke.

Lambert-Eaton Myasthenic Syndrome (LEMS): This presynaptic disorder can resemble botulism but typically presents with proximal weakness, post-tetanic potentiation (strength improves after sustained contraction), and is associated with small cell lung cancer in 50-60% of cases.7

Pearl #2: In any patient presenting with acute bilateral cranial neuropathies and descending weakness without sensory loss or fever, consider botulism until proven otherwise.

The Four Toxinotypes: Foodborne, Wound, Infant, and Iatrogenic

Clostridium botulinum produces eight distinct neurotoxin serotypes (A, B, C, D, E, F, G, and recently identified H), but human disease primarily involves types A, B, E, and rarely F.8 Understanding the four major clinical forms is crucial for appropriate management.

1. Foodborne Botulism

Epidemiology: The classic form, accounting for approximately 15% of US cases but up to 65% globally. The median incubation period is 12-36 hours (range: 2 hours to 8 days), inversely proportional to toxin load.9

Source: Home-canned foods with low acidity (pH >4.6) are the principal culprits in the US—vegetables, fish, and fruits. Commercial products are rarely implicated due to strict food safety regulations. In Alaska, fermented marine mammal products represent a unique risk factor.

Clinical presentation: Multiple patients from a common food source may present simultaneously with symmetric bulbar symptoms progressing to respiratory failure. Gastrointestinal prodrome (nausea, vomiting, abdominal cramps) occurs in 30-50% of cases.

Hack: Always inquire about recent consumption of home-canned goods, fermented foods, or unrefrigerated garlic-in-oil preparations. A single patient with botulism may herald a larger outbreak requiring public health intervention.

2. Wound Botulism

Epidemiology: Increasingly common, now representing 20-30% of US cases, with a dramatic rise associated with black tar heroin use, particularly through subcutaneous injection ("skin popping").10

Pathophysiology: Spores of C. botulinum germinate in necrotic tissue under anaerobic conditions, producing toxin in vivo. The incubation period is longer than foodborne botulism (median 7-10 days).

Clinical pearls:

Absence of gastrointestinal prodrome distinguishes wound from foodborne botulism
Fever may be present due to concurrent wound infection
The wound may appear benign or even be healing by presentation
Consider in any injection drug user presenting with flaccid paralysis

Diagnostic approach: Wound debridement specimens should be sent for anaerobic culture and toxin analysis. Serum toxin assays may be negative despite active disease, as toxin is produced locally.

Pearl #3: In the era of the opioid epidemic, wound botulism should be considered in any person who injects drugs presenting with bulbar symptoms, even without an obvious wound.

3. Infant Botulism

Epidemiology: The most common form in the US (70% of cases), affecting infants <12 months, with peak incidence at 2-4 months.11

Pathophysiology: Ingestion of spores (commonly from honey or environmental dust) leads to intestinal colonization and in vivo toxin production. The immature infant gut microbiome facilitates germination.

Classic presentation: "Floppy baby syndrome"

Constipation (often the first sign, present in 90% of cases)
Poor feeding and weak cry
Progressive hypotonia and weakness
Loss of head control
Dilated pupils with sluggish light reflex
Decreased gag reflex

Spectrum: Ranges from mild hypotonia and constipation to fulminant respiratory failure requiring mechanical ventilation.

Management nuances:

Human-derived botulism immune globulin (BIG-IV or BabyBIG®) is the treatment of choice, reducing hospital stay from 5.7 weeks to 2.6 weeks and decreasing mechanical ventilation requirements.12
Avoid aminoglycosides, which can potentiate neuromuscular blockade
Antibiotics are generally contraindicated unless for secondary infections, as bacterial lysis may increase toxin release

Oyster: Sudden infant death syndrome (SIDS) investigations occasionally reveal evidence of C. botulinum colonization, suggesting botulism may contribute to some SIDS cases.13

4. Iatrogenic (Cosmetic/Therapeutic) Botulism

Context: With over 7 million cosmetic botulinum toxin procedures performed annually in the US, iatrogenic botulism, while rare, represents an emerging concern.14

Causes:

Dosing errors: Confusion between units of different formulations (Botox®, Dysport®, Xeomin®) which are not interchangeable
Counterfeit or unlicensed products: Particularly from international sources
Therapeutic overdose: In treatment of dystonia, spasticity, or hyperhidrosis

Presentation: Onset typically within 24-72 hours of injection with disproportionate weakness of muscles near injection sites, followed by generalized symptoms. Respiratory compromise can occur with high doses.

Management: Supportive care is primary; heptavalent antitoxin is generally not indicated for therapeutic botulinum toxin complications unless systemic symptoms develop, as the risk-benefit ratio is unfavorable.

Pearl #4: Bioterrorism potential—Botulinum toxin is classified as a Category A bioterrorism agent. A cluster of previously healthy adults presenting with descending flaccid paralysis without an obvious food source should prompt consideration of intentional release and immediate notification of public health authorities.

The Edrophonium (Tensilon) Test Revisited: What it Can and Cannot Tell You

The edrophonium test, once a cornerstone of neuromuscular junction disorder diagnosis, has fallen out of favor in many centers but retains utility in select situations.

Pharmacology and Mechanism

Edrophonium is a short-acting acetylcholinesterase inhibitor (duration: 5-10 minutes) that increases acetylcholine concentration at the neuromuscular junction. In myasthenia gravis, where the defect is postsynaptic (reduced acetylcholine receptors), increased acetylcholine improves neuromuscular transmission and transiently reverses weakness.15

In botulism, the defect is presynaptic (impaired acetylcholine release), and edrophonium typically produces no improvement or paradoxical worsening. However, this is not absolute.

Test Protocol

Preparation:

Establish IV access
Cardiac monitoring (risk of bradycardia, hypotension)
Atropine 0.5-1.0 mg available at bedside for muscarinic side effects
Resuscitation equipment immediately available

Administration:

Test dose: 2 mg IV (to assess for hypersensitivity)
If tolerated, administer 8 mg IV over 60 seconds
Observe for 5 minutes for objective improvement in muscle strength

Endpoint: Improved ptosis, extraocular movements, or limb strength

Interpretation in Botulism

What the test CAN tell you:

A positive test (clear improvement) makes botulism unlikely and supports myasthenia gravis
Helps differentiate presynaptic from postsynaptic neuromuscular junction disorders

What the test CANNOT tell you:

A negative test does not confirm botulism, as it can be negative in both botulism and seronegative myasthenia gravis
Some botulism cases show partial or equivocal responses, particularly in wound botulism or with types E and F toxin16
The test has low sensitivity and specificity for botulism diagnosis

Oyster: Approximately 10-20% of botulism cases may show modest improvement with edrophonium, particularly early in the disease course when some acetylcholine release capacity remains. This can lead to diagnostic confusion and delayed antitoxin administration.

Modern Alternatives

Electrodiagnostic testing has largely superseded the edrophonium test:

Repetitive Nerve Stimulation (RNS):

Low-frequency (2-3 Hz) stimulation shows decremental response in both MG and botulism
High-frequency (20-50 Hz) stimulation shows incremental response (>100% increase) in botulism and LEMS, but decremental in MG
The incremental response in botulism may be less pronounced than in LEMS17

Single-Fiber EMG (SFEMG):

Most sensitive test, showing increased jitter and blocking
Abnormal in virtually 100% of cases but non-specific (also abnormal in MG, LEMS, and other neuromuscular disorders)

Pearl #5: While waiting for confirmatory toxin assays (which can take days), electrodiagnostic testing can provide supportive evidence within hours and guide early therapeutic decisions. A typical botulism pattern shows normal sensory responses, normal or low-amplitude motor responses, and facilitation >100% on high-frequency stimulation.

Current Role

The edrophonium test may still be useful when:

Electrodiagnostic testing is unavailable
Rapid bedside differentiation between MG and botulism is needed to guide empiric therapy
There is diagnostic uncertainty in resource-limited settings

However, clinical assessment and electrodiagnostic studies have replaced edrophonium testing in most modern critical care units, particularly given the test's limited sensitivity and specificity and potential for adverse effects (bradycardia, bronchospasm, syncope).

Securing the Heptavalent Botulism Antitoxin (BAT): A Logistics Challenge

Botulism antitoxin represents the only specific therapy that can halt disease progression, but securing it requires navigating a complex logistics chain. Time is of the essence, as antitoxin can only neutralize circulating toxin—it cannot reverse established neuromuscular blockade.

Understanding Botulism Antitoxin

Historical context: The original equine-derived antitoxin was bivalent (types A and B) and later trivalent (A, B, and E). The current formulation is heptavalent botulism antitoxin (HBAT or BAT), containing antibodies against toxin types A, B, C, D, E, F, and G.18

Formulation:

Equine-derived F(ab')2 fragments
Supplied as a lyophilized powder requiring reconstitution
Administered as a single dose IV infusion over 30-60 minutes

Efficacy: Antitoxin reduces mortality and shortens duration of illness when administered early. Studies suggest a 50% reduction in mechanical ventilation duration and hospital length of stay when given within 24 hours of symptom onset.19 Beyond 72 hours, benefits diminish significantly.

The Procurement Process: A Step-by-Step Guide

Step 1: Clinical suspicion

Do not wait for laboratory confirmation—clinical diagnosis is sufficient
Consider botulism in any patient with acute bilateral cranial neuropathies and descending paralysis

Step 2: Immediate notification Contact your state health department immediately (24/7 availability):

Provide clinical details and epidemiologic information
State health departments have direct access to CDC protocols

Step 3: CDC involvement

State health department contacts the CDC Emergency Operations Center (770-488-7100)
CDC clinical botulism service provides consultation
If clinical syndrome is consistent, CDC releases antitoxin

Step 4: Antitoxin delivery

BAT is stored in strategic locations (quarantine stations) nationwide
Delivery arranged within hours (typically 4-12 hours)
CDC coordinates transport via commercial or military means

Step 5: Administration

Skin testing no longer routinely recommended (delays treatment, low predictive value)
Premedication with antihistamine (diphenhydramine) and H2 blocker
Close monitoring during infusion (risk of hypersensitivity, serum sickness)

Hack: Save time by contacting your state health department and CDC simultaneously while completing your clinical evaluation. Have the following information ready:

Patient demographics and timeline of symptom onset
Detailed food history (last 7 days) or drug use history
Clinical examination findings (especially cranial nerve abnormalities)
Results of any laboratory or electrodiagnostic testing

Special Considerations

Infant botulism: BAT is NOT used in infants. Instead, BabyBIG® (Botulism Immune Globulin Intravenous) is obtained through the California Department of Public Health Infant Botulism Treatment and Prevention Program (1-510-231-7600, available 24/7).20 BabyBIG is human-derived, eliminating serum sickness risk.

Adverse reactions to equine-derived antitoxin:

Immediate hypersensitivity: 2-3% (urticaria, bronchospasm, anaphylaxis)
Serum sickness: 10-20% (fever, rash, arthralgias, typically 7-14 days post-infusion)
Have epinephrine and resuscitation equipment immediately available

Oyster: The single greatest impediment to favorable outcomes in botulism is delayed recognition and late antitoxin administration. Studies consistently show that mortality and morbidity increase proportionally with time from symptom onset to antitoxin administration.21 When in doubt, call early—the CDC can provide expert consultation to guide decision-making.

Laboratory Confirmation

While antitoxin should be administered based on clinical suspicion alone, laboratory confirmation is essential for public health purposes and definitive diagnosis.

Specimens to collect BEFORE antitoxin administration:

Serum (20-30 mL preferred)
Stool (25-50 g)
Gastric aspirate (if <3 days from ingestion)
Wound specimens (tissue, drainage) if wound botulism suspected
Suspected food samples

Testing methodology:

Mouse bioassay (gold standard): Detects and types toxin with high sensitivity but requires 24-96 hours
ELISA: Faster but less sensitive
Culture: Organism isolation possible but insensitive

Pearl #6: Serum toxin assays are positive in only 30-40% of confirmed wound and infant botulism cases but remain positive in 60-70% of foodborne cases. A negative serum toxin does not exclude botulism.22

The Long Road of Recovery and the Role of Neurorehabilitation

Unlike many critical illnesses with rapid recovery trajectories, botulism convalescence is measured in weeks to months, demanding patience, multidisciplinary support, and comprehensive rehabilitation strategies.

Pathophysiology of Prolonged Recovery

Botulinum toxin produces irreversible cleavage of SNARE proteins (synaptosomal-associated protein receptors) essential for vesicle fusion and neurotransmitter release. Recovery requires:

Sprouting of new nerve terminals (axonal sprouting)
Formation of new neuromuscular junctions
Regeneration of cleaved SNARE proteins
Functional reinnervation of muscle fibers

This biological reconstruction explains the protracted recovery, typically following this timeline:23

Weeks 1-2: Plateau or worsening despite antitoxin (ongoing toxin absorption and binding)
Weeks 2-4: Stabilization, beginning of cranial nerve recovery
Weeks 4-12: Gradual improvement in limb strength, weaning from ventilator
Months 3-6: Continued strength gains, functional independence emerging
Months 6-12: Subtle deficits persist (fatigue, mild weakness, autonomic dysfunction)

Oyster: Some patients report persistent symptoms (fatigue, exertional dyspnea, dysautonomia) for years after acute illness, possibly related to incomplete reinnervation or chronic fatigue syndrome-like sequelae.24

Critical Care Phase: Weeks to Months

Respiratory management:

Early intubation threshold: Vital capacity <30% predicted, negative inspiratory force >-30 cmH2O, or progressive bulbar dysfunction with aspiration risk
Tracheostomy should be considered early (within 7-10 days) given the anticipated prolonged ventilation (median 4-8 weeks)
Weaning is gradual; spontaneous breathing trials should begin once FVC >10-12 mL/kg

Nutritional support:

Early enteral nutrition via nasogastric or post-pyloric feeding tube
High protein requirements (1.5-2.0 g/kg/day) to counter catabolism
Careful attention to gastric motility (ileus common due to autonomic dysfunction)

Complications to anticipate:

Ventilator-associated pneumonia: Major cause of morbidity and mortality
ICU-acquired weakness: Superimposed critical illness polyneuromyopathy compounds botulism weakness
Venous thromboembolism: Prolonged immobility necessitates pharmacologic prophylaxis
Pressure injuries: Meticulous skin care and frequent repositioning essential
Autonomic instability: Labile blood pressure, cardiac arrhythmias, urinary retention

Hack: Avoid neuromuscular blocking agents if possible, as they can obscure neurologic assessment and may prolong paralysis. If paralysis is necessary (e.g., severe ARDS), use agents that can be monitored with train-of-four (though responses may be atypical).

Neurorehabilitation: The Path to Recovery

Early mobilization:

Passive range-of-motion exercises initiated immediately to prevent contractures
Progressive mobilization as strength returns: bed exercises → sitting → standing → ambulation
Physical and occupational therapy consultation within 48 hours of ICU admission

Respiratory rehabilitation:

Inspiratory muscle training once spontaneous breathing begins
Assisted cough techniques
Secretion clearance protocols (mechanical insufflation-exsufflation if needed)
Gradual ventilator weaning with daily spontaneous breathing trials

Swallowing rehabilitation:

Speech-language pathology evaluation for dysphagia
Modified barium swallow study when clinically appropriate
Graded diet advancement from NPO → thin liquids → regular diet
Many patients require prolonged enteral nutrition (weeks) before safe oral intake

Psychological support:

Depression and PTSD common in survivors of prolonged critical illness
Cognitive dysfunction (ICU delirium sequelae) may require neuropsychological rehabilitation
Family support and education crucial

Pearl #7: Establish realistic expectations early. Patients and families often expect rapid recovery after antitoxin administration. Clearly communicate that recovery takes months and that return to baseline function may be incomplete, particularly in severe cases or older patients.

Outpatient Recovery and Long-Term Follow-Up

Month 1-3 post-discharge:

Continued outpatient physical and occupational therapy
Frequent neurologic reassessment
Pulmonary function testing in previously ventilated patients
Nutritional optimization (many patients lose 10-20% body weight)

Month 3-12:

Gradual return to activities of daily living
Vocational rehabilitation for return to work
Continued exercise prescription and strength training
Monitoring for long-term sequelae

Long-term outcomes:

90-95% of patients eventually achieve functional independence25
Complete recovery is the rule in young, previously healthy individuals
Older patients and those with comorbidities may have residual deficits
Mortality in modern era: 3-5% with optimal supportive care

Multidisciplinary Team Approach

Successful botulism management requires coordination among:

Intensivists: Respiratory and hemodynamic management
Neurologists: Diagnostic confirmation, electrophysiologic monitoring
Infectious disease specialists: Wound management in wound botulism
Physical medicine and rehabilitation: Long-term functional recovery
Respiratory therapists: Ventilator management and weaning
Physical/occupational therapists: Mobility and ADL retraining
Speech-language pathologists: Dysphagia management
Dietitians: Nutritional optimization
Social workers: Discharge planning and psychosocial support
Public health officials: Outbreak investigation and prevention

Conclusion

Botulism represents the intersection of toxicology, neurology, critical care, and public health. For the intensivist, recognizing the "descending" paralysis pattern, understanding the four distinct toxinotypes, navigating the logistics of antitoxin procurement, and committing to prolonged supportive care and rehabilitation are essential competencies. While rare, botulism carries significant morbidity and potential mortality without prompt recognition and treatment.

The differential diagnosis of acute flaccid paralysis is broad, but key clinical features—bilateral cranial neuropathies, descending progression, autonomic dysfunction, and absence of sensory deficits—should trigger consideration of botulism. When suspected, immediate contact with public health authorities and rapid antitoxin administration can be life-saving. Finally, preparing patients and families for the extended recovery trajectory and ensuring comprehensive neurorehabilitation support are critical to optimizing long-term outcomes.

In an era of emerging infectious diseases and bioterrorism threats, maintaining vigilance for botulism and its mimics remains a fundamental responsibility of critical care practitioners.

References

Arnon SS, Schechter R, Inglesby TV, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA. 2001;285(8):1059-1070.
Sobel J. Botulism. Clin Infect Dis. 2005;41(8):1167-1173.
Cherington M. Clinical spectrum of botulism. Muscle Nerve. 1998;21(6):701-710.
Kongsaengdao S, Samintarapanya K, Rusmeechan S, et al. An outbreak of botulism in Thailand: clinical manifestations and management of severe respiratory failure. Clin Infect Dis. 2006;43(10):1247-1256.
Hughes JM, Blumenthal JR, Merson MH, et al. Clinical features of types A and B food-borne botulism. Ann Intern Med. 1981;95(4):442-445.
Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016;388(10045):717-727.
Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011;10(12):1098-1107.
Rossetto O, Pirazzini M, Montecucco C. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol. 2014;12(8):535-549.
Shapiro RL, Hatheway C, Swerdlow DL. Botulism in the United States: a clinical and epidemiologic review. Ann Intern Med. 1998;129(3):221-228.
Werner SB, Passaro D, McGee J, et al. Wound botulism in California, 1951-1998: recent epidemic in heroin injectors. Clin Infect Dis. 2000;31(4):1018-1024.
Koepke R, Sobel J, Arnon SS. Global occurrence of infant botulism, 1976-2006. Pediatrics. 2008;122(1):e73-e82.
Arnon SS, Schechter R, Maslanka SE, et al. Human botulism immune globulin for the treatment of infant botulism. N Engl J Med. 2006;354(5):462-471.
Arnon SS, Midura TF, Damus K, et al. Intestinal infection and toxin production by Clostridium botulinum as one cause of sudden infant death syndrome. Lancet. 1978;1(8077):1273-1277.
Cote TR, Mohan AK, Polder JA, et al. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol. 2005;53(3):407-415.
Benatar M. A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul Disord. 2006;16(7):459-467.
Maselli RA, Bakshi N. Botulism. In: Katirji B, Kaminski HJ, Ruff RL, eds. Neuromuscular Disorders in Clinical Practice. 2nd ed. Springer; 2014:1239-1256.
Tim RW, Sanders DB. Repetitive nerve stimulation studies in the Lambert-Eaton myasthenic syndrome. Muscle Nerve. 1994;17(9):995-1001.
Cangene Corporation. BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)] Package Insert. Health Canada; 2013.
Tacket CO, Shandera WX, Mann JM, et al. Equine antitoxin use and other factors that predict outcome in type A foodborne botulism. Am J Med. 1984;76(5):794-798.
Underwood K, Rubin S, Deakers T, Newth C. Infant botulism: a 30-year experience spanning the introduction of botulism immune globulin intravenous in the intensive care unit at Childrens Hospital Los Angeles. Pediatrics. 2007;120(6):e1380-e1385.
Wilcox P, Morrison NJ, Pardy RL. Recovery of the ventilatory and upper airway muscles and exercise performance after type A botulism. Chest. 1990;98(3):620-626.
Hatheway CL. Botulism: the present status of the disease. Curr Top Microbiol Immunol. 1995;195:55-75.
Dressler D, Saberi FA. Botulinum toxin: mechanisms of action. Eur Neurol. 2005;53(1):3-9.
Therre H. Botulism in the European Union. Euro Surveill. 1999;4(1):2-5.
Mann JM, Martin S, Hoffman R, Marrazzo S. Patient recovery from type A botulism: morbidity assessment following a large outbreak. Am J Public Health. 1981;71(3):266-269.

Author Disclosure: The author has no conflicts of interest to disclose.

Word Count: 5,247 (including abstract and references)

Note: This review article is intended for educational purposes for postgraduate trainees in critical care medicine. Clinical decisions should be individualized and made in consultation with appropriate specialists and public health authorities.

learningmedicine

Sunday, October 26, 2025

Botulism and its Mimics